Manufactor:Bigbear Pharmaceutical Laos
Introduction:CAPIVADX (Capivasertib) 200 mg 64 Film-Coated Tablets. First-in-class AKT inhibitor (targets PI3K/AKT/mTOR pathway)
Indications:
Treatment of hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with specific PIK3CA/AKT1/PTEN alterations, in combination with fulvestrant, after progression on endocrine-based therapy.
Dosage & Administration
Standard Dose:
● 200 mg tablet taken twice daily (morning and evening, ~12 hours apart).
● Dosing schedule: 4 days on, 3 days off (e.g., Monday–Thursday, then skip Friday–Sunday).
● Take with food (improves absorption; avoid grapefruit).
● Swallow whole—do not crush, split, or chew.
Missed Dose:
● If ≤4 hours late, take immediately.
● If >4 hours late, skip and resume the next scheduled dose.
● Never double dose.
Dose Adjustments:
● First reduction: 160 mg twice daily.
● Second reduction: 120 mg twice daily.
● Discontinue if toxicity persists after dose reduction.
Precautions
1. Hyperglycemia (High Blood Sugar)
● Monitor blood glucose before starting and regularly during treatment.
● May require antidiabetic medications (e.g., metformin, insulin).
2. Diarrhea
● Can be severe; manage with antidiarrheals (e.g., loperamide) and hydration.
● Interrupt treatment if Grade 3+ diarrhea occurs.
3. Skin Reactions
● Rash, dry skin, or nail changes may occur.
● Use moisturizers and sunscreen; avoid harsh skincare products.
4. Liver Toxicity
● Monitor LFTs (ALT/AST) before and during treatment.
5. Drug Interactions
● Avoid strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin)—may increase toxicity.
● Avoid strong CYP3A inducers (e.g., rifampin, carbamazepine)—may reduce effectiveness.
Common Side Effects
● Diarrhea, nausea, vomiting
● Fatigue, headache
● Hyperglycemia, decreased appetite
● Rash, dry skin, nail disorders
Storage
Store at room temperature (20–25°C) in original packaging, away from moisture.
Note: Genetic testing (PIK3CA/AKT1/PTEN alterations) is required before use.